1416 Results

People

  1. Motzer
    Motzer
  2. Vickers
    Vickers
  3. Hudis
    Hudis
  4. Norton
    Norton
  5. Saltz
    Saltz
  6. O'Reilly
    O'Reilly
  7. Mao
    Mao
  8. Morris
    Morris
  9. Seidman
    Seidman
  10. Kris
    Kris

Groups

  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)
  7. Hematologic Malignancies, Division of (169)
  8. Genitourinary Oncology Service (160)
  9. Center for Hematologic Malignancies (142)
  10. Gastrointestinal Oncology Service (126)
  1. "randomized controlled trial"
Formats
  1. Journal Article (1353)
  2. Review (19)
  3. Conference Paper (17)
  4. Editorial (9)
  5. Correspondence (5)
  6. Research Letter (5)
  7. Meeting Abstract (4)
  8. Guidelines (3)
  9. Book Section (1)
Groups
  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)

More Groups

People
  1. Robert Motzer (83)
  2. Andrew Vickers (48)
  3. Larry Norton (34)
  4. Clifford Hudis (33)
  5. Leonard Saltz (32)
  6. Eileen O'Reilly (25)

More People

Years
  1. 2025 (63)
  2. 2024 (165)
  3. 2023 (110)
  4. 2022 (81)
  5. 2021 (39)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (164)
  2. New England Journal of Medicine (65)
  3. Lancet Oncology (46)
  4. Cancer (42)
  5. Clinical Cancer Research (42)
  6. European Urology (26)

More Publications

Publishers
  1. Elsevier Inc. (187)
  2. American Society of Clinical Oncology (170)
  3. Elsevier Science, Inc. (138)
  4. Springer (79)
  5. Lippincott Williams & Wilkins (72)
  6. Wiley Blackwell (71)

More Publishers

Results (1416)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I and randomized phase II study of ruxolitinib with frontline neoadjuvant therapy in advanced ovarian cancer: An NRG Oncology Group Study
    Journal Article

    Landen, C. N.; Buckanovich, R. J.; Sill, M. W.; Mannel, R. S.; Walker, J. L.; Disilvestro, P. A.; Mathews, C. A.; Mutch, D. G.; Hernandez, M. L.; Martin, L. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR)
    Journal Article

    Ahluwalia, M. S.; Peereboom, D. M.; Ozair, A.; Khosla, A. A.; Ozair, A.; Rudek, M.; Ye, X.; Holdhoff, M.; Grossman, S. A.; Ye, X.; more...
    Cell Reports Medicine (2024)

    Fulltext@MSK | Save
  • A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
    Journal Article

    Lara, P. N.; Villanueva, L.; Ibanez, C.; Erman, M.; Lee, J. L.; Heinrich, D.; Lipatov, O. N.; Gedye, C.; Gokmen, E.; Acevedo, A.; more...
    BMC Cancer (2024)

    Fulltext@MSK | Save
  • Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: Final analysis of clinically relevant subgroups in GRIFFIN
    Journal Article

    Chari, A.; Kaufman, J. L.; Laubach, J.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; Silbermann, R.; Costa, L. J.; Anderson, L. D.; Nathwani, N.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
    Journal Article

    Garrido, C.; Manoogian, M.; Ghambire, D.; Lucas, S.; Karnoub, M.; Olson, M. T.; Hicks, D. G.; Tozbikian, G.; Prat, A.; Ueno, N. T.; more...
    Virchows Archiv (2024)

    Fulltext@MSK | Save
  • Protocol for a randomized controlled trial of brief behavioral activation among older adult cancer survivors
    Journal Article

    Saracino, R. M.; Park, E. Y.; Demirjian, C.; Jutagir, D. R.; McConnell, K. M.; Schofield, E.; Raue, P. J.; Lejuez, C. W.; Nelson, C. J.
    Journal of Geriatric Oncology (2024)

    Fulltext@MSK | Save
  • Transperineal versus transrectal magnetic resonance imaging–targeted and systematic prostate biopsy to prevent infectious complications: The PREVENT randomized trial
    Journal Article

    Hu, J. C.; Assel, M.; Allaf, M. E.; Ehdaie, B.; Vickers, A. J.; Cohen, A. J.; Ristau, B. T.; Green, D. A.; Han, M.; Rezaee, M. E.; more...
    European Urology (2024)

    Fulltext@MSK | Save
  • Characterization of responses to lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma at the final prespecified survival analysis of the phase 3 CLEAR study
    Journal Article

    Motzer, R. J.; Choueiri, T. K.; Hutson, T.; Young Rha, S.; Puente, J.; Lalani, A. K. A.; Winquist, E.; Eto, M.; Basappa, N. S.; Tannir, N. M.; more...
    European Urology (2024)

    Fulltext@MSK | Save
  • A whole food, plant-based randomized controlled trial in metastatic breast cancer: feasibility, nutrient, and patient-reported outcomes
    Journal Article

    Campbell, E. K.; Campbell, T. M.; Culakova, E.; Blanchard, L.; Wixom, N.; Guido, J. J.; Fetten, J.; Huston, A.; Shayne, M.; Janelsins, M. C.; more...
    Breast Cancer Research and Treatment (2024)

    Fulltext@MSK | Save
  • Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study
    Journal Article

    Nooka, A. K.; Kaufman, J. L.; Rodriguez, C.; Jakubowiak, A.; Efebera, Y.; Reeves, B.; Wildes, T. M.; Holstein, S. A.; Anderson, L. D. Jr; Badros, A.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save